Subscribe to RSS
DOI: 10.1055/a-2524-3553
Outcomes of endoscopic submucosal dissection for high-risk colorectal colitis-associated neoplasia in inflammatory bowel disease

Abstract
Background Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer. High-risk colorectal colitis-associated neoplasia (HR-CAN) can be difficult to treat using traditional endoscopic resection methods. This study evaluated the outcomes of endoscopic submucosal dissection (ESD) in patients with IBD and HR-CANs.
Methods This retrospective multicenter study consecutively included patients with IBD who were referred to expert Italian endoscopy centers for ESD or hybrid ESD (hESD) of HR-CANs. The main outcomes were rates of en bloc, R0, and curative resections, adverse events, local recurrence, metachronous lesions, and post-resection surgery. Kaplan–Meier method was used to analyze survival rates. Risk factors associated with the main outcomes were investigated by univariable analysis.
Results 91 patients with colonic IBD (disease duration 15.3 [SD 8.7] years, 82.4 % with ulcerative colitis) with 96 HR-CANs (mean size 34.8 [SD 16.2] mm, 53.1 % high grade dysplasia/adenocarcinoma) were included. ESD and hESD were performed in 82.3 % and 17.7 %, respectively. En bloc, R0, and curative resections were achieved in 95.8 % (95 %CI 89.6–98.8), 85.4 % (95 %CI 76.7–91.7), and 83.3 % (95 %CI 74.3–90.1). Adverse events occurred in 12.5 % (95 %CI 6.6–20.8), which were all conservatively managed. After a mean follow-up of 23.4 (SD 16.1) months, local recurrence and metachronous lesions each occurred in 3.1 %. Post-resection surgery was required in 11.5 %.
Conclusions ESD of HR-CANs showed favorable outcomes on the medium- and long-term course in patients with IBD.
Publication History
Received: 25 May 2024
Accepted after revision: 23 January 2025
Accepted Manuscript online:
23 January 2025
Article published online:
24 February 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology 2022; 162: 715-730
- 2 Olén O, Erichsen R, Sachs MC. et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020; 395: 123-131
- 3 Olén O, Erichsen R, Sachs MC. et al. Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol 2020; 5: 475-484
- 4 Lutgens MWMD, van Oijen MGH, van der Heijden GJMG. et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19: 789-799
- 5 Jess T, Horváth-Puhó E, Fallingborg J. et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013; 108: 1869-1876
- 6 Nardone OM, Zammarchi I, Santacroce G. et al. Inflammation-driven colorectal cancer associated with colitis: from pathogenesis to changing therapy. Cancers (Basel) 2023; 15: 2389
- 7 Zhao M, Gönczi L, Lakatos PL. et al. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis 2021; 15: 1573-1587
- 8 Stidham RW, Higgins PDR. Translational research in colorectal cancer: colorectal cancer in inflammatory bowel disease. Clin Colon Rectal Surg 2018; 31: 168
- 9 Shah SC, Itzkowitz SH. Management of IBD-associated dysplasia in the modern era. Gastrointest Endosc Clin N Am 2019; 29: 531
- 10 Choi CHR, Rutter MD, Askari A. et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol 2015; 110: 1022-1034
- 11 Axelrad JE, Shah SC. Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. Therap Adv Gastroenterol 2020; 13: 1756284820920779
- 12 Gordon H, Biancone L, Fiorino G. et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis 2023; 17: 827-854
- 13 Rabinowitz LG, Kumta NA, Marion JF. Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease. Gastrointest Endosc 2022; 95: 30-37
- 14 Murthy SK, Feuerstein JD, Nguyen GC. et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 2021; 161: 1043-1051
- 15 Kabir M, Thomas-Gibson S, Tozer PJ. et al. DECIDE: Delphi expert consensus statement on inflammatory bowel disease dysplasia shared management decision-making. J Crohns Colitis 2023; 17: 1652-1671
- 16 Kabir M, Thomas-Gibson S, Hart AL. et al. Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace affiliation: results of an international clinician survey. J Crohns Colitis 2022; 16: 39-48
- 17 Kabir M, Thomas-Gibson S, Hart AL. et al. Management of inflammatory bowel disease associated colonic dysplasia: factors predictive of patient choice and satisfaction. Colorectal Dis 2021; 23: 882-893
- 18 Shergill AK, Lightdale JR, Bruining DH. et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-1121
- 19 Bak MTJ, Albéniz E, East JE. et al. Endoscopic management of patients with high-risk colorectal colitis-associated neoplasia: a Delphi study. Gastrointest Endosc 2023; 97: 767-779
- 20 Lobatón T, Bessissow T, De Hertogh G. et al. The Modified Mayo Endoscopic Score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients. J Crohns Colitis 2015; 9: 846-852
- 21 Daperno M, D’Haens G, Van Assche G. et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512
- 22 Cremer A, Demetter P, De Vos M. et al. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. Clin Gastroenterol Hepatol 2020; 18: 1528-1536
- 23 Meulen LWT, van der Zander QEW, Bogie RMM. et al. Evaluation of polypectomy quality indicators of large nonpedunculated colorectal polyps in a nonexpert, bowel cancer screening cohort. Gastrointest Endosc 2021; 94: 1085-1095
- 24 Jacques J, Schaefer M, Wallenhorst T. et al. Endoscopic en bloc versus piecemeal resection of large nonpedunculated colonic adenomas: a randomized comparative trial. Ann Intern Med 2024; 177: 29-38
- 25 Singh RR, Nanavati J, Gopakumar H. et al. Colorectal endoscopic submucosal dissection in the West: a systematic review and meta-analysis. Endosc Int Open 2023; 11: E1082-E1091
- 26 McCarty TR, Bazarbashi AN, Thompson CC. et al. Hybrid endoscopic submucosal dissection (ESD) compared with conventional ESD for colorectal lesions: a systematic review and meta-analysis. Endoscopy 2021; 53: 1048-1058
- 27 Wang J, Yang B, Chandra J. et al. Preventing fibrosis in IBD: update on immune pathways and clinical strategies. Expert Rev Clin Immunol 2024; 20: 727-734
- 28 Hirai M, Yanai S, Kunisaki R. et al. Effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration study. Gastrointest Endosc 2023; 98: 806-812
- 29 Maselli R, de Sire R, Massimi D. et al. Advancements in endoscopic resection for colitis-associated colorectal neoplasia in inflammatory bowel disease: turning visible into resectable. Diagnostics (Basel) 2023; 14: 9